HR Execs on the Move

Stelexis Therapeutics

www.stelexis.com

 
Stelexis` mission is to become the leading cancer therapeutics company, through the discovery and development of novel drugs, utilizing its proprietary platform to selectively target pre-cancerous stem cells. The company will initially focus on therapeutics for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Patrick Doyle
Chief Executive Officer Profile

Similar Companies

Trillium Therapeutics

Trillium Therapeutics is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Celtic Pharma (Main) US

Celtic Pharma (Main) US is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lybradyn Inc

Lybradyn Inc is a Oak Brook, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

XtalPi

XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform.

Adagio Therapeutics

Adagio Therapeutics, Inc` is a clinical-stage a biotechnology company developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional pre-emergent coronaviruses` Our candidates are optimized using Adimab’s industry-leading antibody engineering capabilities and are designed to provide patients and clinicians with an unsurpassed combination of potency, breadth, durable protection (via half-life extension), manufacturability, tolerability, and affordability` Our portfolio of SARS-CoV-2 antibodies includes multiple, non-competing antibodies with distinct binding epitopes` Pre-clinical data show that our lead antibody ADG20 matches or exceeds the potency and coverage of other clinical SARS-CoV-2 antibody programs` We plan to advance ADG20 aggressively through global clinical trials for both the prevention and treatment of symptomatic COVID-19 and anticipate data from both prevention and treatment clinical trials in 2021` Adagio has secured manufacturing capacity for the production of ADG20 with third party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch`